Consistent with CDX findings, PRMT1 knockdown significantly inhibited tumor growth, and tumors in the PRMT1 siRNA group showed heightened CBP sensitivity (Figure 2D–F; Figure S4G, Supporting Information). Here, PRMT1 is linked to neoplasm.